首页> 美国卫生研究院文献>PLoS Clinical Trials >In situ Biological Dose Mapping Estimates the Radiation Burden Delivered to ‘Spared’ Tissue between Synchrotron X-Ray Microbeam Radiotherapy Tracks
【2h】

In situ Biological Dose Mapping Estimates the Radiation Burden Delivered to ‘Spared’ Tissue between Synchrotron X-Ray Microbeam Radiotherapy Tracks

机译:原位生物剂量图估计了同步加速器X射线微束放射治疗轨迹之间传递到“备用”组织的辐射负担

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Microbeam radiation therapy (MRT) using high doses of synchrotron X-rays can destroy tumours in animal models whilst causing little damage to normal tissues. Determining the spatial distribution of radiation doses delivered during MRT at a microscopic scale is a major challenge. Film and semiconductor dosimetry as well as Monte Carlo methods struggle to provide accurate estimates of dose profiles and peak-to-valley dose ratios at the position of the targeted and traversed tissues whose biological responses determine treatment outcome. The purpose of this study was to utilise γ-H2AX immunostaining as a biodosimetric tool that enables in situ biological dose mapping within an irradiated tissue to provide direct biological evidence for the scale of the radiation burden to ‘spared’ tissue regions between MRT tracks. Γ-H2AX analysis allowed microbeams to be traced and DNA damage foci to be quantified in valleys between beams following MRT treatment of fibroblast cultures and murine skin where foci yields per unit dose were approximately five-fold lower than in fibroblast cultures. Foci levels in cells located in valleys were compared with calibration curves using known broadbeam synchrotron X-ray doses to generate spatial dose profiles and calculate peak-to-valley dose ratios of 30–40 for cell cultures and approximately 60 for murine skin, consistent with the range obtained with conventional dosimetry methods. This biological dose mapping approach could find several applications both in optimising MRT or other radiotherapeutic treatments and in estimating localised doses following accidental radiation exposure using skin punch biopsies.
机译:使用高剂量同步加速器X射线的微束放射疗法(MRT)可以破坏动物模型中的肿瘤,而对正常组织的损害很小。在微观尺度上确定在MRT过程中传递的辐射剂量的空间分布是一项重大挑战。薄膜和半导体剂量测定法以及蒙特卡洛方法难以在其生物学反应决定治疗结果的目标组织和遍历组织的位置提供准确的剂量分布和峰谷剂量比估计值。这项研究的目的是利用γ-H2AX免疫染色作为生物剂量学工具,该工具能够在受辐照的组织内进行原位生物剂量定位,从而为MRT轨道之间“稀疏”组织区域的辐射负荷规模提供直接的生物学证据。 Γ-H2AX分析允许对成纤维细胞培养物和小鼠皮肤进行MRT处理后,在束之间的谷中追踪微束并定量DNA损伤灶,其中单位剂量的病灶产量比成纤维细胞培养低约五倍。使用已知的宽束同步加速器X射线剂量,将位于山谷中细胞的病灶水平与校准曲线进行比较,以生成空间剂量分布图,并计算细胞培养的峰谷剂量比为30–40,鼠皮的峰谷比为60,与常规剂量法获得的范围。这种生物剂量定位方法可以在优化MRT或其他放射治疗方法以及使用皮肤穿刺活检术意外辐射暴露后估算局部剂量方面找到几种应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号